Page 7 - Derek Wallace News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda’s dengue vaccine candidate suggest that it could help with outbreak prevention REPUBLIKA.CO.ID, JAKARTA -- Takeda Pharmaceutical Company Limited (Takeda) announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual's previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES enrolled more than 20.000 healthy children and adolescents a...

Vaccine candidate demonstrated 83.6% efficacy against hospitalisation three years after vaccination - News - PharmaTimes

Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results | 2021-05-25 09:45:00

Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot’s ...

− Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety ...